Key result
The N588K mutation attenuated hERG current inhibition by antiarrhythmic drugs in the order of E-4031 > amiodarone > quinidine > propafenone > disopyramide.
Population
CHO cells expressing wild-type and mutant (N588K, S631A and N588K/S631A) hERG potassium channels
Comparison
Five hERG-blocking drugs vs Wild-type hERG channels and other…
Design
Preclinical
Authors
Loading...
Amiodarone may be effective for SQT1 in vitro; leaves open need for clinical validation before practice change.
The inhibitory potency of antiarrhythmic drugs on hERG channels depends on the level of channel inactivation, highlighting amiodarone as a potential candidate for treating SQT1.
McPate et al. (2008) studied Short QT syndrome (SQTS). hERG-blocking drugs (E-4031, amiodarone, quinidine, propafenone, disopyramide) vs. Wild-type hERG channels was evaluated on hERG current (I(hERG)) inhibition. The N588K mutation attenuated hERG current inhibition by antiarrhythmic drugs in the order of E-4031 > amiodarone > quinidine > propafenone > disopyramide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: